A086450 Stock Overview
Produces and sell pharmaceutical products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for A086450 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
DongKook Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩16,140.00 |
| 52 Week High | ₩20,600.00 |
| 52 Week Low | ₩14,990.00 |
| Beta | 0.65 |
| 1 Month Change | -7.45% |
| 3 Month Change | -4.78% |
| 1 Year Change | 0.88% |
| 3 Year Change | -25.62% |
| 5 Year Change | -10.33% |
| Change since IPO | 225.81% |
Recent News & Updates
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Investors Are Less Pessimistic Than Expected
Aug 07
These 4 Measures Indicate That DongKook Pharmaceutical (KOSDAQ:086450) Is Using Debt Reasonably Well
May 29Recent updates
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Investors Are Less Pessimistic Than Expected
Aug 07These 4 Measures Indicate That DongKook Pharmaceutical (KOSDAQ:086450) Is Using Debt Reasonably Well
May 29We Think DongKook Pharmaceutical (KOSDAQ:086450) Can Stay On Top Of Its Debt
May 06DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 06How Much Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Do Insiders Own?
Mar 15The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Has Gained 136%, So Why Not Pay It Some Attention?
Feb 28DongKook Pharmaceutical Co., Ltd.'s (KOSDAQ:086450) Stock Is Going Strong: Is the Market Following Fundamentals?
Feb 14
DongKook Pharmaceutical (KOSDAQ:086450) Seems To Use Debt Quite Sensibly
Feb 01DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jan 19The Attractive Combination That Could Earn DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) A Place In Your Dividend Portfolio
Jan 06DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Dec 24With EPS Growth And More, DongKook Pharmaceutical (KOSDAQ:086450) Is Interesting
Dec 21What Kind Of Investors Own Most Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)?
Dec 08The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Is Up 177% And Shareholders Are Boasting About It
Nov 23Shareholder Returns
| A086450 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -2.7% | 1.5% | -1.6% |
| 1Y | 0.9% | 3.2% | -9.1% |
Return vs Industry: A086450 underperformed the KR Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: A086450 exceeded the KR Market which returned -9.1% over the past year.
Price Volatility
| A086450 volatility | |
|---|---|
| A086450 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A086450 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A086450's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 1,131 | Heung-Ju Oh | www.dkpharm.co.kr |
DongKook Pharmaceutical Co., Ltd. produces and sell pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, and cosmetics. Its pipeline includes DKF-310, which is in preclinical trials for the treatment of dementia; DKM-413, used for anesthetic; DKF-361, used to treat hypertension; DKF-325, an anticoagulant; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, that is in clinical studies, indicated for benign prostatic hyperplasia; DKF-340, a nonsteroidal anti-inflammatory drugs; DKM-415, indicated for synovial fluid replacement; DKF-334 and DKF-335 to treat osteoporosis; and DKF-363, for treatment of respiratory inflammation.
DongKook Pharmaceutical Co., Ltd. Fundamentals Summary
| A086450 fundamental statistics | |
|---|---|
| Market cap | ₩709.65b |
| Earnings (TTM) | ₩61.64b |
| Revenue (TTM) | ₩789.11b |
11.5x
P/E Ratio0.9x
P/S RatioIs A086450 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A086450 income statement (TTM) | |
|---|---|
| Revenue | ₩789.11b |
| Cost of Revenue | ₩350.32b |
| Gross Profit | ₩438.79b |
| Other Expenses | ₩377.15b |
| Earnings | ₩61.64b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.40k |
| Gross Margin | 55.61% |
| Net Profit Margin | 7.81% |
| Debt/Equity Ratio | 10.1% |
How did A086450 perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield13%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 21:43 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DongKook Pharmaceutical Co., Ltd. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mujinn Lee | Cape Investment & Securities Co., Ltd. |
| null null | DBS Bank Ltd |
| Hyuk Jin Yoon | Eugene Investment & Securities Co Ltd. |